Telix and Regeneron Announce Strategic Radiopharma Collaboration
This image was generated by AI and may not depict real events.
Telix Pharmaceuticals and Regeneron Pharmaceuticals have announced a strategic collaboration to co-develop and co-commercialize next-generation radiopharmaceutical therapies. The collaboration combines Telix's expertise in radiopharmaceutical development and manufacturing with Regeneron's leading antibody discovery and development platforms and oncology experience.
Telix Pharmaceuticals and Regeneron Pharmaceuticals are collaborating to develop next-generation radiopharmaceutical therapies. The partnership combines Telix's radiopharmaceutical development platform with Regeneron's biologics expertise. Telix will receive $40 million upfront for four initial programs. The companies will share costs and profits equally. They plan to develop radio-diagnostics to support patient selection and treatment response assessment. The collaboration aims to bring new treatment options to patients with hard-to-treat cancers.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.